Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
Abstract Background While tumor suppressor p53 functions primarily as a transcription factor in the nucleus, cellular stress can cause p53 to translocate to the mitochondria and directly trigger a rapid apoptotic response. We have previously shown that fusing p53 (or its DNA binding domain, DBD, alo...
Saved in:
Main Authors: | Phong Lu (Author), Erica R. Vander Mause (Author), Katherine E. Redd Bowman (Author), Sarah M. Brown (Author), Lisa Ahne (Author), Carol S. Lim (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting mutant p53 stabilization for cancer therapy
by: Jiajian Wang, et al.
Published: (2023) -
p53 A Guardian of the Genome and Beyond
Published: (2022) -
Human Tumor-Derived p53 Mutants: A Growing Family of Oncoproteins
by: Giovanni Blandino
Published: (2016) -
Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish
by: Seok-Hyung Kim, et al.
Published: (2013) -
Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer
by: Katherine Redd Bowman, et al.
Published: (2019)